Welcome to BioNTech's fourth quarter and full year 2023 earnings call. I would like to hand the call over to Dr. Victoria Meissner, Vice President of Strategy and Investor Relations. Please go ahead. Thank you. Good morning, and good afternoon. Thank you for joining BioNTech's fourth quarter and full year 2023 earnings call. As a reminder, the slides we'll be using during this call and the corresponding press release we issued this morning, can be found in the Investor Relations section of our website. On the next slide, you will see our forward-looking statements disclaimer. Additional information about these statements and other risks are described in our filings with the U.S. Securities and Exchange Commission. Forward-looking statements in this call are subject to significant risks and uncertainties, speak only as of the date of this conference call, and we undertake no obligation to update or revise any of these statements. On slide three, you can find the agenda for today's call. Today, I'm joined by the following members of BioNTech's management team: Uğur Şahin, our CEO and Co-founder, Özlem Türeci, Chief Medical Officer and Co-founder, Jens Holstein, Chief Financial Officer, and Ryan Richardson, Chief Strategy Officer. With this, I would like to hand over to Uğur. Thank you, Victoria. A warm welcome to all those joining us today. Slide five. Let me start by reiterating our vision and company goals. BioNTech was founded 15 years ago with the vision to harness the power of the immune system to fight human diseases, particularly cancer. The emergence of the pandemic accelerated our mission, leading to the development of our COVID-19 vaccine. This achievement not only showcased the versatility of our mRNA technology, but also highlighted our unique expertise and ability to execute fast. Our vision was realized and broadened, illuminating the potential of our science across other therapeutic areas. Building on this, our three objectives moving forward are: to establish a multi-product company powered by our pioneering technologies and science to address medical needs worldwide. To contribute to the development of innovative precision medicines against cancer, aiming for multiple product approvals in the coming years, and to expand and strengthen our sustainable respiratory infectious disease vaccine business, building on the success of our Comirnaty franchise. Slide six. On the next slide, I want to talk about our clinical achievements in 2023. We successfully advanced our clinical pipeline and enhanced our technology platforms, digital capabilities and infrastructure by executing across our key strategic initiatives. We continued to develop and empower our innovative oncology and infectious disease pipelines. Today, we have over 20 programs in oncology and seven programs in infectious disease being evaluated in more than 40 clinical trials, including multiple phase II or phase III clinical trials. I'm particularly excited about our recent achievements in shaping our oncology pipeline. We started seven clinical trials and licensed 6 clinical assets throughout the year. Most importantly, several assets have advanced to mid- and late-stage development, with phase II and phase III clinical trials ongoing. These trials feature antibody-drug conjugates, mRNA vaccines, and novel IO therapies in indications such as non-small cell lung cancer, breast and endometrial cancer, adjuvant colorectal cancer, and adjuvant pancreatic cancer. In infectious disease, we started three first-in-human phase I clinical trials, leveraging our proprietary mRNA vaccine technology, including candidates being evaluated against shingles, tuberculosis, and mpox. Over the course of 2024, we aim to advance and prioritize additional product candidates to late-stage development. We expect to have 10 or more potential registrational trials running. Slide seven. The field of oncology is currently undergoing a significant shift away from traditional chemotherapy towards combination therapies. This shift leverages the power of immuno-oncology and antibody-drug conjugates to potentially transform also advanced cancers into manageable conditions. As we reflect on the achievements of 2023, we can proudly say that we have accelerated our IO and ADC programs by not only starting new trials, but also successfully recruiting over 2,000 patients into our clinical trials across various indications. This is a testament to the hard work and dedication of our team and our collaboration partners, as well as the trust and willingness of patients to participate in our studies. Looking ahead to 2024, we aim to build on this success and recruit patients into our clinical trials across indications such as lung cancer, breast cancer, colorectal cancer, and other indications. Slide eight. In 2023, we successfully executed strategic investments, acquisitions, licensing agreements, and public-private partnerships, enabling our continued progress towards building a multi-product, AI-powered, patient-centric company. Since our foundation, we have placed a strong emphasis on computational medicine, data science, artificial intelligence, and machine learning. With the acquisition of InstaDeep, we are integrating capabilities in supercomputing, AI research, and generative AI into various processes. For example, to identify and optimize molecules, to predict biological and clinical outcomes, and to speed up our workflow. In 2023, we expanded our technology base to include ADCs by initiating new collaborations with DualityBio and MediLink Therapeutics. We believe ADCs have the potential to supplement or replace highly toxic chemotherapy regimens as a new combination backbone of cancer treatment. Our collaborations with OncoC4 and Biotheus complement our toolkit of technologies with next generation IO antibodies, that offer unique mechanisms of action, and have augmented our oncology pipeline with mid to late-stage clinical programs. We have started strongly in 2024 on the collaboration front by announcing a strategic alliance with Autolus, aimed at advancing both companies' autologous CAR-T-cell programs towards commercialization. With this collaboration, we will support the development and commercialization of Autolus' lead cell therapy candidate, obe-cel, and retain options to participate in its AUTO1/22 and AUTO6NG programs. Importantly, we have the option to use Autolus commercial and cell therapy manufacturing infrastructure in a cost-efficient manner. This is of relevance for our plans to extend the development of BNT211 to additional Claudin6 positive tumor types, and thus realize its full potential. Slide nine. BNT211 is our CAR-T-cell therapy targeting Claudin6. To improve CAR-T-cell engraftment and persistence, we co-developed a CAR-T-cell amplifying RNA vaccine, or CARvac for short. BNT211 is one example of BioNTech's novel, novel combination. The goal is to enhance persistence and effective function of CAR-T-cells by repeated administration of CARvac. Recently, we presented data suggesting a favorable effect of CARvac on CAR-T-cell persistence in our clinical trial with Claudin6 tumor. Based on the promising early clinical results, we believe that BNT211 has the potential to make a significant impact in patients with Claudin6 positive tumors. Our near-term strategy is to establish Claudin6 as a proven target in solid tumors, and to establish BNT211 as the first CAR-T-cell therapy in germ cell tumors. Claudin6 is broadly expressed in solid cancers including ovarian, lung, gastric, pediatric cancers, and others. Upcoming data will inform the development path for other tumor indications. Slide 10. In 2024, we will continue building a portfolio of compound classes that have synergistic mechanisms of action, including immunomodulators, targeted therapies, and mRNA vaccines. We believe that combination of these therapies, if approved, could play an important role in the efforts towards potentially curative approaches. With that, I would like to thank you all for your confidence in our success and your continued support. I will now turn the call over to Özlem Türeci, who will speak about our oncology pipeline. Thank you, Uğur. Glad to be speaking with everyone today. Starting on slide 12, with an overview of our oncology pipeline. In 2023, we and our partners reported data across our portfolio at multiple medical meetings, including ASCO and ESMO, and we published manuscripts in peer-reviewed journals. More data readouts are expected this year, starting at AACR on BNT122, our individualized neoantigen-based cancer vaccine in resected PDAC, and on BNT116, our off-the-shelf cancer vaccine in non-small cell lung cancer. In 2023, we advanced and expanded our pipeline considerably, and now have multiple mid- to late-stage trials ongoing. Our aim is to continue to progress our oncology pipeline towards pivotal data readouts and submissions for regulatory approvals in the next 18 months. Slide 13, here on the left are the ongoing trials in mid- to late-stage development. The three on top of the list were initiated in 2023. BNT316, an anti-CTLA-4 in IO-experienced non-small cell lung cancer, BNT323, an anti-HER2 ADC in HER2-low breast cancer, and BNT122, our individualized cancer vaccine in the adjuvant pancreatic cancer space. On the right are the product candidates based on ADC, IO, mRNA cancer vaccine modalities, for which we are planning to initiate additional phase II and phase III trials. These programs include validated and novel targets, as well as in-house and in-licensed assets with unique modes of action. We believe we have multiple shots on goal. Our in-licensed assets are starting to contribute to value creation and towards de-risking our pipeline. We plan to explore potential combination product candidates featuring these assets based on the scientific rationale, preclinical and clinical evidence, and also thinking of future treatment sequencing in different indications to provide options for patients along their disease journey. As shown in slide 14, in 2023, we began building a pipeline of ADC candidates that now includes third-generation ADCs directed against four distinct targets. These four targets collectively cover a wide range of cancer types. Our reason for adding this modality to our clinical multi-platform pipeline is that we believe ADCs will transform the oncology space and become broadly used backbones of combination treatment. Our strategy for acquiring these specific assets was based on their potentially differentiated profile, the objective of covering multiple cancer types, and the broad markets they may address. BNT323, a HER2-targeting ADC, is our most advanced ADC. It also is one of the front runners in our clinical pipeline. Now, on Slide 15, BNT323 is a third-generation ADC that aims to overcome the drawbacks of first- and second-generation ADCs to achieve high stability in circulation, low risk of target payload delivery, a high drug-antibody ratio of eight, and an expanded therapeutic window. It is comprised of a humanized anti-HER2 IgG antibody covalently attached to a potent proprietary DNA topoisomerase I inhibitor via a stable maleimide tetrapeptide linker, selectively cleavable by cathepsins that are upregulated in tumor cells. BNT323, binding to HER2 on the surface of tumor cells, inhibits HER2 signaling, followed by internalization of the ADC-HER2 receptor complex, cleavage of the linker, and release of the membrane-permeable payload. The effect is not only killing of these tumor cells, but also bystander killing of neighboring tumor cells, regardless of their HER2 expression levels. In preclinical studies with other third-generation ADCs in animal models, BNT323 was observed to have higher stability, lower levels of free payload and circulation, and more efficient payload release within tumor cells, and stronger anti-tumor activity, including in HER2-low models. On Slide 16 now, BNT323 is currently being evaluated in a signal-seeking phase I/II clinical trial for HER2-expressing advanced solid tumors. The dose expansion part of the phase I/II study is enrolling pretreated patients with advanced or metastatic HER2-expressing solid tumors. As of February of this year, more than 300 patients have received BNT323 in this phase I/II trial. The first data from this study were presented at ASCO last year. We reported preliminary anti-tumor activity in heavily pretreated patients with HER2-expressing solid tumors. Responses were observed in patients treated with different dose levels and with different HER2 expression status. Based on our findings in these dark green-marked cohorts on the right, we have initiated potentially registrational trials in patients with endometrial cancer and breast cancer. On Slide 17, in the breast cancer cohorts of our phase I/II trial, the 26 patients with HER2-positive cancer, which means high and intermediate levels of HER2 expression, showed an objective response rate of 50% and a disease control rate of 96.2%. The 13 patients with HER2-low breast cancer, that have a particularly high medical need, had an objective response rate of 38.5% and a disease control rate of 84.6%. BNT323 was observed to be well-tolerated, and all adverse events were manageable. Interstitial lung disease of grade one occurred in two out of these 85 patients. Based on these data, we initiated a phase III study of BNT323 in chemotherapy-naïve patients with hormone receptor-positive, HER2-low breast cancer, whose disease has progressed on prior endocrine therapy, with or without CDK4/6 inhibition in the metastatic setting, versus investigators' choice of chemotherapy. As shown in Slide 18, in the U.S., the U.K., the EU4, and Japan, approximately 700,000 patients per year are diagnosed with breast cancer. The majority of those achieve remission through surgery or the initial therapy. Those that do not get cured are being treated with hormonal and targeted therapies and chemotherapy. First generations of HER2 targeting antibodies only benefited those 30% of patients with high or intermediate expression levels of HER2, designated as HER2 positive. More recently, patients with HER2-low expression, that comprise two-thirds of the remaining 70% breast cancer patients, have been shown to benefit substantially from new generation HER2-targeted ADC therapy. HER2-directed ADCs are currently only approved for chemotherapy-experienced patients, meaning from first line onwards. In our ongoing phase III study, we are targeting chemo-naive patients from second line onwards, as marked here in dark green. Slide 19. Coming back to our phase I/II trial and the findings in endometrial cancer patients with advanced, recurrent, or metastatic HER2-positive and HER2-low tumors. For endometrial cancer, we received Fast Track Designation and Breakthrough Designation from the FDA in 2023. In September 2023, clinical data from 17 patients with endometrial cancer were presented at the ASCO annual meeting. All patients had received one or more treatment lines, including immunotherapy, anti-HER2 antibody, or endocrine therapy. The BNT323 shows promising anti-tumor activity across different HER2 expression levels, including IHC 1+ expression, which is low expression, with an objective response rate of 58.8%, of which 35.5% are pending confirmation. The disease control rate was 94.1%. While the sample size is still small and data cut-off is too early to draw conclusions on less frequent treatment, emergent adverse events, and TEAEs with protracted manifestation, the safety profile was manageable and no new safety signals were observed. Slide 20. Patients with advanced, unresectable, or recurrent endometrial cancer receive treatment based on their molecular profile. The latest clinical data support adding immunotherapy to chemotherapy as a frontline treatment for patients with stage four endometrial cancer and dMMR status. Patients who overexpress HER2 can be treated with HER2-targeting therapies, such as trastuzumab, in combination with chemotherapy as a frontline treatment. Despite the recent advancements in frontline treatment, most patients relapse. At present, there is no targeted therapy approved for patients who progress on first-line treatment and whose tumor expresses HER2. This is the patient population we are currently focusing on with the BNT323. Slide 21. I would like to re-emphasize that our aim for 2024 is to further advance our key programs into late-stage development, with the aim of contributing to the next generation of oncology medicines that could include candidates featured on this slide. We believe our investments and efforts will pave the way for an initial wave of oncology product launches from 2026 onwards. I now pass the presentation to our CFO, Jens Holstein. Thank you, Özlem, and a warm welcome to everyone who has dialed in today's call. 2023 was another successful year for BioNTech on its journey to develop novel therapies for cancer and infectious diseases. Let me highlight three main points here. We kept our global COVID-19 vaccine market leadership. We grew and advanced our late-stage pipeline, and we again delivered a strong financial performance, highlighted by EUR 3.8 billion of total recognized revenues, EUR 1.2 billion of profit before tax, resulting in earnings per share on a fully diluted basis of EUR 3.83. With this, we ended the 2023 financial year with approximately EUR 17.7 billion of cash, cash equivalents, and security investments. Turning to the next slide. While our financial performance in 2023 was strong and we were able to maintain profitability, there were also some financial challenges that we had to navigate through. In our third quarter earnings call last year, we updated our full year 2023 COVID-19 vaccine revenue guidance to around EUR 4 billion, reflecting write-downs in the amount of approximately EUR 600 million by our collaboration partner, Pfizer. In Q4, Pfizer recognized additional write-downs of approximately EUR 300 million that negatively impacted our top-line figure compared to our initial expectations for Q4. The negative impact on our revenue for 2023 accumulated to a total of approximately EUR 900 million. Write-downs related to aged inventory would typically have a negative impact on the gross profit in a P&L. Following our gross profit share agreement with Pfizer, write-downs by our partner have a negative effect on BioNTech's revenue figure. That made our revenue guidance for 2023 challenging. Having said that, the agreement has an important advantage. BioNTech only requires very little commercial infrastructure in the COVID-19 vaccine franchise, and with this, has low expenses related to sales and marketing in comparison to other players in the field. This is, we believe, favorable, as Comirnaty is a leading brand in the global COVID-19 vaccine market. Despite the decrease in our revenues in 2023, and despite the negative impact of these write-downs, we were able to both remain profitable in 2023 and grew our year-end financial position in respect of cash, cash equivalents, and security investments to EUR 17.7 billion, compared to EUR 13.9 billion at the end of 2022. Please note that the contractual settlement of the gross profit share has a temporal offset of more than one calendar quarter. In addition, Pfizer's financial quarter for the subsidiaries outside the United States differs from ours. I'll be moving now to the summary of our financial results for the fourth quarter of 2023 and full year of 2023, as shown on the next slide. For the three months ended December 31, 2023, we recognized EUR 1.5 billion in COVID-19 vaccine revenues, compared to EUR 4.3 billion for the comparative period in 2022. For the financial year 2023, our total reported revenues reached EUR 3.8 billion, compared to seventeen point three billion euros in 2022. This was primarily driven by lower COVID-19 vaccine market demand, and as stated before, write-downs reported by our collaboration partner, Pfizer, which negatively influenced our revenues. Moving to cost of sales. Cost of sales amounted to EUR 179 million in the fourth quarter of 2023, in line with the EUR 183.5 million for the comparative prior year period. For the 2023 financial year, the cost of sales amounted to close to EUR 600 million, compared to approximately EUR 3 billion in 2022. The drop was mainly caused by the decrease in COVID-19 vaccine sales. Research and development expenses reached EUR 578 million for the fourth quarter of 2023, compared to EUR 510 million for the comparative period in 2022. For the 2023 financial year, research and development expenses amounted to approximately EUR 1.8 billion, compared to EUR 1.5 billion in 2022. The increase was mainly influenced by progressing clinical studies for pipeline candidates, as well as by our newly acquired product candidates and the development of variant-adapted COVID-19 vaccines. In line with a higher headcount compared to the previous year, too, for example, support our existing clinical trials and future growth initiatives, we also saw respective higher costs and wages, benefits, and social security expenses in the financial year 2023. General and administrative expenses amounted to approximately EUR 0.1 billion for both the fourth quarter of 2023, as well as for the comparative period in 2022. For the 2023 financial year, general and administrative expenses remained at EUR 0.5 billion, around the same level as in the previous year. A slight increase in G&A was mainly influenced by increased expenses for IT services, as well as by wages, benefits, and Social Security expenses, resulting from an increase in headcount. Income taxes were accrued with an amount of EUR 205.3 million for the fourth quarter of 2023, compared to EUR 893.9 million for the comparative period in 2022. For the 2023 financial year, income taxes were accrued with an amount of EUR 255.8 million, compared to EUR 3.5 billion in 2022. The derived effective income tax rate for the 2023 financial year was 21.6%, roughly in line with our expectations of around 21%, improved versus last year's tax rate of 27%. For the fourth quarter of 2023, net profit reached EUR 457.9 million, compared to EUR 2.3 billion in the comparative period in 2022. For the year ended December 31, 2023, net profit reached EUR 0.9 billion, compared to EUR 9.4 billion in 2022. Our diluted earnings per share for the fourth quarter of 2023 amounted to EUR 1.90, compared to EUR 9.26 for the comparative period in 2022. For the 2023 financial year, our diluted earnings per share amounted to EUR 3.83, compared to EUR 37.77 in 2022. Let's continue with the next slide. This shows the 2023 financial guidance provided to you during our Q3 earnings call in November 2023, in comparison with the actuals for the 2023 financial year. Starting from the top, we recognized EUR 3.8 billion of COVID-19 vaccine revenues, compared to our guidance of around EUR 4 billion. Approximately EUR 300 million additional write-downs by our collaboration partner had to be unexpectedly recognized in Q4. Moving to R&D expenses. During the 2023 financial year, our R&D expenses were nearly EUR 1.8 billion, slightly below our amended guidance from November of 2023 of EUR 1.8 billion-EUR 2 billion. Lower spending in, for example, other collaborations, have been a main contributor, as well as strong cost control measures. Our co-R&D activities in 2023 focused on broadening and accelerating our existing pipeline of product candidates in oncology and infectious diseases, in line with our expectations. Moving to SG&A expenses. During the 2023 financial year, we recognized EUR 558 million in SG&A expenses, slightly below the lower end of our amended guidance of EUR 600 million-EUR 650 million. Again, we were closely monitoring our spending to reflect the uncertainty on the revenues without jeopardizing the future needs in this area. Moving to CapEx. Our 2023 financial year capital expenditures for operating activities amounted to EUR 276 million, whereof the majority was related to investment in building our laboratory and office facilities in Mainz, Germany. The spending is in line with our expectations, ranging from EUR 200 million-EUR 300 million. Lastly, tax. As already mentioned, during the 2023 financial year, we reached an annual effective income tax rate of 21.6%, which is roughly in line with our amended guidance of around 21%. Turning to the next slide, showing the 2024 financial year guidance. Let me highlight now some key aspects of the company's outlook for the 2024 financial year. Starting with total revenues for the BioNTech group, we expect total revenues in the range of EUR 2.5 billion-EUR 3.1 billion for 2024. In providing a range estimate today, we take, to some extent, potential up and down sides into account. For example, we assume largely the same vaccination rate for the US market, but have seen some price pressure in the US in Q4, some smaller inventory write-down with by our collaboration partner, Pfizer, as we have faced, again, additional write-downs above the previous announced ones that hit our revenue figure in Q4 2023. We also assume that we generate revenues from a pandemic preparedness contract with the German government in 2024. For the 2024 financial guidance, we expect our R&D expenses to be in the range of EUR 2.4 billion-EUR 2.6 billion, while our SG&A expenses are expected to be in the range of EUR 700 million-EUR 800 million. Please note that anticipated expenses related to the external legal advice in connection with legal litigations is not reflected in SG&A, but in other operating expenses. Additionally, the guidance does not include, but may be impacted by potential payments resulting from any collaboration agreements or in-licensing deals, M&A transactions or outcomes of ongoing or future legal disputes or related activities such as judgment for settlements. Lastly, capital expenditures for the 2024 financial year are expected to be in the range of EUR 400 million-EUR 500 million. In 2024, we will be increasing our operating expenses in R&D and SG&A to accelerate BioNTech's transition into a multi-product oncology and infectious disease company with a commercial footprint. For that, we want to increase our investments to lift the potential value that we see in our portfolio of product candidates. In 2023, we in-licensed multiple assets to bolster our late-stage pipeline. This year, we will invest in progressing our candidates into later-stage trials to fuel BioNTech's next stage of growth. As previously mentioned, we aim to have 10 or more potentially registrational clinical trials ongoing by the end of 2024. With this, we pave the way for multiple potential product approvals, estimated to begin with first launch in 2026. As previously indicated, 2024 will be a transition year for our company, during which we will continue to invest in our long-term growth strategy while maintaining strict cost discipline. Overall, during this transition year, our revenues will be driven largely by the uptake of our COVID-19 vaccines in the second half of 2024. As a consequence of the expected revenue range, in taking into account cost of sales, R&D, and all other expenses, we do not expect to be profitable in 2024. Turning to the next slide. Today, BioNTech has a leading and profitable COVID-19 vaccine business. As you can see on the slide, our COVID-19 vaccine business benefited from its lean, fixed cost structure in 2023 and generates very attractive positive results. In the coming years, we aim to invest alongside our partner in bringing variant-adapted and potentially combination vaccines to market, with a goal to further contributing to our future value generation. In addition to our value-contributing COVID-19 vaccine franchise, we are investing into long-term value creation with our multiple product oncology pipeline. Let me highlight three value drivers. We plan to have 10 or more potentially registrational trials ongoing by the end of 2024. We aim to have a first potential oncology launch in 2026, adding to our top line. And thirdly, we believe to have a diversified clinical pipeline that offers multiple product growth opportunities for the years to come. Summarizing, we believe that our COVID-19 vaccine franchise and our innovative pipeline of product candidates will drive long-term value creation for the company. Our Chief Strategy Officer, Ryan Richardson, will now talk you through some of the strategic drivers for this transformation. Thank you. Thank you, Jens. To wrap up our prepared remarks, I'll provide a high-level overview of our 2030 strategy and the path to value creation from our mid- and late-stage oncology pipeline programs before concluding with a few important dates to mark on your calendars. On the next slide, we highlight the broad value creation opportunities underpinning our 2030 strategy. Our balance sheet has been further strengthened in 2023 and will continue to serve as a strategic asset to fuel long-term growth. We will continue to invest behind our market-leading COVID-19 vaccine franchise, leveraging our partnership with Pfizer across R&D, manufacturing, and commercial functions.... On a product contribution basis, we expect this franchise to continue to be highly cash generative. We are working with Pfizer to develop a COVID-19 and influenza combination vaccine, which is successful in late-stage trials, could reach the market as early as fall 2025. We are ramping up our investments into our expanding and diverse late-stage oncology pipeline. Our goal is to have at least 10 trials initiated with registrational potential by the end of this year. We believe this broad pipeline can deliver multiple new commercial product launches in the years ahead. Finally, we will continue to invest to industrialize our mRNA vaccine platform to address infectious diseases with high unmet global need. Today, we have five infectious disease vaccines beyond COVID-19 in phase I clinical trials. By 2030, we aim to bring our first vaccines from this pipeline to market, complemented by an expanding late-stage infectious disease vaccine pipeline. Our 2030 strategy aims to transform BioNTech into a diversified, cash flow generating, multi-product company that can deliver sustained long-term growth. Turning to the next slide, I would like to spend a little more time today on the growth potential of our expanding late-stage pipeline. This pipeline includes seven mid and late-stage programs that are currently in phase II and phase III trials. We have mentioned our goal to have 10+ trials with registrational potential initiated by the end of 2024. We also expect a busy calendar of program updates this year. These include updates on several cancer vaccine programs at AACR, which were announced last week, and further anticipated updates for specific IO and ADC programs at other major medical conferences throughout the year. 2024 will therefore be an important year of execution as we transition toward our goal of commercializing our oncology portfolio. We are looking forward to sharing further details on these programs throughout the course of the year. Ultimately, we believe our oncology pipeline can deliver one or more indication launches per year from 2026 onwards. We see significant potential for our mid and late-stage programs to address unmet medical need across a broad range of cancer types and across the cancer treatment continuum. We are truly excited by the potential our oncology pipeline holds to expand and improve on cancer treatment options for people around the world. In closing, I would like to highlight on the next slide a few important investor events we will be holding this year. Our annual general meeting will take place on May seventeenth, and the next innovation series event on November fourteenth. This year, we will also introduce a new and exciting event focused on our expanding work in the field of artificial intelligence and machine learning, which will take place on October first. We look forward to sharing further details on both events in the near future. With that, I would like to thank our shareholders for their continued support and open the floor for questions. Thank you. To ask a question, you will need to press star one and one on your telephone and wait for your name to be announced. To withdraw your question, please press star one and one again. We will now go to your first question. One moment, please. Your first question comes from the line of Daina Graybosch from Leerink Partners. Please go ahead. Yeah, thank you, guys. Thanks for the update and the question. As you look forward to these 10 potential registrational trials, I wonder if you can talk about, maybe even a range of revenue expectations, that you could be looking at by 2030 from the oncology portfolio, and then I have a follow-up. Yes, thanks. Thanks, Daina. You know, I think the pipeline's quite broad, and one of the criteria that is common among most of those assets in that list is actually that they can target multiple solid tumors. And so that means that actually the peak sales estimate for that collection of assets is actually well over EUR 10 billion in our range long term, in our estimates long term. And but I think we're focused now on executing in those first launches, so I think we're not prepared yet to give you a 2030 number. But we do think that we're talking here about, you know, double-digit indications that we can address across the solid tumor landscape. Great, thank you. And then my follow-up is more specific on the Autolus collaboration. I wonder if you could talk about potential scenarios for how you see your CAR-T business with Autolus maturing and advancing in the next five years. Sure, so I'll start with that, too. So the primary rationale for Autolus was that as we ended 2023, we actually had higher conviction on moving forward more aggressively with BNT211, which is our lead cell therapy CAR-T program, as you know, targeting Claudin6 with an mRNA vaccine amplifier. And so we've talked about testicular cancer being a potential lead indication and a potential fast-to-market path, given the high unmet need in the refractory setting. But we're also seeing strong and encouraging data in other indications, such as refractory ovarian cancer and even seeing responses in lung cancer and other Claudin6 positive tumors. So the Autolus collaboration gives us a sort of runway to more aggressively explore multiple pivotal trials in parallel, leveraging the manufacturing infrastructure that we have in the United States through the Kite acquisition of assets that we had 2.5 years ago, but also combined with the Autolus state-of-the-art manufacturing infrastructure in the United Kingdom. So that's the first rationale. And then in addition to that, the deal incorporates some options, where we could come in at the pivotal trial stage into a couple of Autolus' programs. We find their phase I data for their AUTO1/22 very encouraging. It's early, but it's encouraging, and also the GD2 CAR, we think is an interesting approach that could be complementary. So the collaboration construct gives us the optionality to actually scale into a multi-product franchise in cell therapy, while keeping our fixed costs lean and allowing us to accelerate BNT211 forward. Great. Thank you. We will now go to the next question. Your next question comes from the line of Chris Shibutani from Goldman Sachs. Please go ahead. Hey, this is Steven on for Chris. Thank you for taking our question. I had one on the financial side. Can you just give a little bit of color about what's driving the increase in SG&A guidance? I think at the midpoint, it's about over 30% increase from the prior year. So just wondering if, if that's related to COVID or if that's more related to building out the oncology franchise. And then specifically on your HER2 ADC, can you just talk about what type of clinical profile would be attractive in that HER2-low breast cancer indication? Thank you. Yeah, thanks for the question. I'll take the first one on the SG&A expense increase that we anticipate for 2024. You, you have heard from, from us that, you know, we're planning to launch, potentially our first product in 2026. Of course, we've got to build up the infrastructure to be able to, to commercialize those compounds, that are coming then in 2026 and onwards, and therefore, you know, we intend to invest in infrastructure, specifically also in, in commercial setup in the U.S. going forward. The second question was what makes for our HER2 ADC the indication of hormone receptor positive HER2-low breast cancer interesting. Did I get that right? More kind of expectations for what type of clinical profile would be attractive in that space? The TPP. So, our HER2 ADC, we think has a differentiable safety efficacy profile, and this is what we want to see in our phase III trial, which is ongoing. Yeah, and just to add on that, what Özlem shared is, we have a profile allowing us to dose, to provide higher doses, and we believe that this is particularly important in the HER2 1+ population, which is around half of the HER2 low population. So particularly, this is interesting in breast cancer as well, in endometrial cancer and other HER2 positive tumors. And we believe that we can position here the product with higher objective response rates, plus higher durability of response. Okay. Thank you very much, team. Thank you. Your next question comes from the line of Bill Mangan from Canaccord Genuity. Please go ahead. Good morning, and thanks. So I have kind of a two-part question about your ability to maintain market share on the COVID vaccine going forward. Just wondering how you're thinking about your ability to, I guess, defend and/or grow that. Just given, for example, I know Arcturus is in Japan with a self-amplifying RNA for COVID, and Moderna has previously made a lot of noise about their prefilled syringe. I know that Pfizer's rolling out a prefilled syringe, but I guess I'm just wondering how widespread that is and if you've seen any competitive advantage where that has become available. Thank you. Yeah, thank you for the question. So we believe that we still performed very strong in 2023 in having globally above a 50% market share for the COVID franchise. We did see some market share pressure in a couple of markets, like the United States, as you point out. We've also had market share gains in a number of other geographies. We maintained a very high market share, above 85%, in Europe, and also grew our market share in countries like Japan, which have actually been pretty sizable from a volume perspective over the last 12 months. Going into 2024, we do feel confident that we can continue to maintain a leadership position above the 50% mark globally. To your question on competition, yes, we do expect there to be some new entrants, mostly niche players in some of the peripheral markets. I think that you pointed out also the role of prefilled syringes, which is an important point. I think last year, it is fair to say that part of the reduction in market share in the United States that we experienced was due to a sort of a lack or limited supply of prefilled syringes. Last year, we did have some supply in the United States, but we also had single-dose vials as well, and clearly the market preference was for prefilled syringes. As we go into 2024, we have taken steps with Pfizer to dramatically increase our supply of prefilled syringes in the United States, but also elsewhere. Thank you. Thank you. Your next question comes from the line of Akash Tewari from Jefferies. Please go ahead. ... Good morning, this is Ivy on for Akash. Thanks for taking our questions. We have two. The first one is on COVID. So for COVID vaccines gross margin, given that Pfizer reported EUR 5.4 billion for revenue versus your EUR 1.5 billion, and that you are splitting gross profit 50/50 with Pfizer, it seems to imply a gross margin of 60%, which is lower than previous levels of around 80%. So is this just because of the additional write-off Pfizer had in Q4? Additionally, I think, what's your view on gross margin in '2024 and beyond for your COVID business, especially when the competitor seems to talk about a higher GTN discount? And my second question is quickly for pipeline. I guess, how encouraged are you with the early signals of BNT122 in other tumors outside of pancreatic? Is there any read across from the pancreatic data that will be presented at AACR soon? Thanks. Yeah, let me take the first question, thanks for the question. To just clarify, you know, Pfizer is, as you know, responsible for the commercialization of, Comirnaty in most markets, with the exception of Germany and Turkey, and we have a gross profit share. That methodology works in a way that, of course, you know, whatever, Pfizer is writing off on, in the, in write-offs on inventories or something like this, will go in the gross profit share and will reduce our revenue figure. That is, you know, what we are trying to highlight, for the last quarters, because we have been hit by around EUR 900 million, and due to that procedure. This means for us, this is basically 100% profit for us before costs that come across due to the manufacturing activities that we are responsible for, and they are limited. And if you compare the margin development that we'll have in 2023 versus 2022, you know, you will see that, you know, we are above 480% margin. So, you can't really read through from what Pfizer's reporting really to our numbers that we report. With regard to your question to our BNT122 and its performance in PDAC, we are very encouraged, not surprised, but really encouraged. This is also the reason why following the data disclosure of our phase I PDAC trial, we have initiated a phase II PDAC trial in the adjuvant setting with BNT122, which is enrolling a patient. The results we saw in this cancer type, which is considered as immune suppressive and cold and low in tumor mutational load, is encouraging us also to go into other cancer indications with this type of immunological profile. In fact, in our phase I trials in other such indications, we have collected data which supports the PDAC findings and which we currently are compiling to be published as manuscripts. Thanks. Thank you. Your next question comes from the line of Yaron Werber from TD Cowen. Please go ahead. Right, good morning, and, thanks for taking that. I have a couple of questions as well. So maybe the first one is on BNT323, the ongoing phase III study, the DYNASTY-Breast02. Can you talk a little bit about the powering on the PFS? And I-- it sounds like, if I remember correctly, chemo, the ORR that historically is 11%-36%, PFS is about 3-8. You showed a 39% ORR. So sort of, it depends how the chemo is gonna do, which is kinda, will determine kind of how the study works. So maybe if you can talk about the powering of the study and maybe a little bit, if you can share any phase I, 2 data on PFS, so we can kinda just get a sense of what you're expecting. And then secondly, just curious, you have such a huge pipeline already, and you've executed and you're obviously continuing to execute, and you need to grow the company a lot to continue to execute. What's the purpose to doing potentially more BD, given that you have so much already? Thank you. Thanks, Yaron. So I'll start with the second question, and then we'll come to the first. So I think, you know, we were obviously very active last year on the BD front, bringing in-house six clinical stage or near clinical stage assets. We are gonna continue to be active, but Yaron, I think we would agree that, you know, we feel that we already have actually now a very broad toolkit that allows us to do a lot. And so we are focused increasingly on execution. So I do think that, you know, we're gonna continue to be active in BD, but probably not as active in terms of the number of clinical stage assets that we're looking to bring on board. We're look... The focus this year is gonna be more on executing and getting the pivotal trials initiated and enrolled. Yeah, to your second question. I think the second question can be better answered with the powering for a hazard ratio, which we usually do around 0.7, yeah, 0.65. ... And with that, we have a power of 90%, yeah. And this gives rise to a study of around 450 patients that we will enroll. Thank you. I will now go to the next question. Your next question comes from the line of Etzer Darout from BMO Capital. Please go ahead. Great, thanks for taking the question. Just, one question from me. On, on BNT327, your VEGF, VEGF, PD-L1, you, you highlighted, the program sort of prominently, a couple of slides and looking at sort of phase IIIs 2024 and beyond. Just wondered if you would be providing any clinical updates, for this program in 2024, and what we could expect to see there, and any more specifics as well on sort of the potential path to phase III and what programs or, or what indications specifically you may, be able to sort of pursue with, with this molecule? Thank you. Yeah, thank you for the question. Indeed, we will see a number of clinical trial updates on this molecule, multiple indications. Just to remind everyone, this is a bispecific molecule which has PD-L1 for PD-1 blocking and anti-VEGF arm. Yeah. What we have seen so far consistently in a number of cohorts is the objective response rates, which are very encouraging in various indications. And what we have also reported already, our first two combination trials in small cell lung cancer and in triple-negative breast cancer patients. What is really exciting in these indications is not only the high response rates in the range of 60%-75% in triple-negative breast cancer patients, but also the response rate in the patient population who are negative for immune infiltrates, which is unusual, yeah, for checkpoint blockade. So we believe that this molecule could that we can replicate this molecule, not only in these two indications, as small cell lung cancer and triple-negative breast cancer, but also in a wider range of indications. This besides allowing us to position the molecule as a combination partner for classical chemotherapy and even more importantly for our ADC portfolio. Thank you. Thank you. Your next question comes from the line of Jessica Fye from JP Morgan. Please go ahead. Hey, guys. Good morning. Thanks for taking my questions. First, on the top-line guidance, I think you previously talked about roughly a EUR 3 billion top line just a couple of months ago, and appreciate you highlighting the variables that factor into the guidance. But can you just expand on which of those assumptions drove the change? And then second, on the pipeline, related to the HER2 space, what are you guys gonna be watching for in the DESTINY-Breast06 readout as it relates to your HER2 ADC? Thank you. So yeah, let me take the first question. So we broadened the range. You know, we felt that the top-line guidance should reflect the assumptions that we've made with respect to the vaccination rates and the price levels that we currently have seen. You know, where Comirnaty, of course, is significantly relevant. We also have made assumptions related to the inventory write-offs that hit us in, back in 2023. And, you know, there will be some write-offs that we've got to anticipate going forward. So we've done some, included here, some assumptions. And, of course, there are also some additional anticipated revenues related to our service business and the German Pandemic Preparedness contract that we have in hand or we are finalizing currently with the government. So therefore, you know, we feel we have that was driving basically the broadening of that range. So, each of those really factored into the broadening? This, you know, there are some upsides, there are some downsides that I mentioned, and, you know, we'll try to work it in with, of course, current assumptions. You know, that could vary over time, but that's what we've done, yes. Got it. Yes, with regard to our HER2 ADC, the concept of HER2 ADCs and the molecules which are around, that's a great concept. That's very obvious, and we are very excited about our HER2 ADC, the molecule, the BNT323, which we have partnered with Duality. And as Uğur pointed out earlier, in HER2-low breast cancer, are looking for making a difference in this high medical need population. You also have heard about our target of hazard ratio, which we are targeting. Yeah, we can't, of course, comment on the clinical trials of third parties. Thank you. Thank you. Your next question comes from the line of Simon Baker from Redburn. Please go ahead. Thank you for taking my question. Two quick ones, if I may. The 2024 R&D guidance- ... of EUR 2.4 billion-EUR 2.6 billion is a step up on 2023. And against the plethora of studies you're running, that makes perfect sense. But I was wondering, is this the new normal? And was wondering what you could say about the anticipated levels of R&D expense beyond 2024. And finally, there's been an awful lot of deal activity in the radiopharmaceutical space of late. I'd be interested to get your thoughts on the attractiveness of that modality. Thanks so much. Yeah, happy to take the first question. So, as you pointed out correctly, of course, you know, we have broadened our portfolio. We have more and more late-stage clinical trials running, and those drive the costs up to a great extent yet. And, going forward, as, you know, we haven't given any guidance here yet for 2025, the following years. So, you know, we, you gotta bear with us, a little bit. But of course, you know, late-stage clinical trials will cost some money. We will carefully look, you know, where we invest our money. You know, we have shown that in 2023 already, where we had the same sort of range at the beginning, and then we reduced costs. Also reflecting, you know, the pressure that we have faced on the top line, regarding the COVID revenue figures that we had to adjust during 2023. So there is some level of insecurity. I think it's part of our job to manage our costs here, and of course, we will do that in 2024 and the ongoing years. But we will invest in the areas where we feel we create value for the company and value for the shareholders. That remains, you know, on top of our list going forward. Yeah, and the second part of your question about attractiveness of radioligands, I would like to say, and repeating myself, is that oncology is being in a transformation, and we will see this transformation ongoing in the next 10-15 years. The transformation happens because there are new concepts, and one of the new concepts is targeting tumor cells, but having bystander effect. And this is what we are seeing in radioligands. So we have this targeting of tumor cells, plus the additional bystander effect, and this is even more pronounced in the ADC field. Yeah, so we will see really tremendous transformation in the oncology, providing us the opportunity to open up indications where we believed in the past patients, we can't offer patients anything. And this is offering now the opportunity to treat patients with advanced diseases and not only with their disease, but bring in combinations and thereby ensure that even in patients with advanced disease, they really get a considerable clinical benefit. Great, thanks so much. Thank you. Your next question comes from the line of Eliana Merle from UBS. Please go ahead. Hi, this is Sarah on for Eliana. Thanks so much for taking our question. Could you remind us the latest thinking about when we could see data from iNeST phase II randomized trial? And what you're hoping to see there that would continue to give you guys confidence in the program and moving forward? Okay. Yeah, so shortly, we will report iNeST data on our melanoma trial this year. Yeah. Latest in the second half of this year, and we expect the next update for our colorectal cancer study end of 2025. Yeah. Great. Thanks. Thank you. We will now go to our final question for today. Your final question comes from the line of Emmanuel Papadakis from Deutsche Bank. Please go ahead. Hello, thank you. So quick question from us, Emmanuel Papadakis, Deutsche Bank. So just wanted to know, what are the first phase III readouts we will see for the rest of the portfolio in 2025 or beyond? And I'm assuming nothing major in 2024. Please correct me if I'm wrong. Thank you. Yeah. Thank you, Manus. So we talked about a couple of different trials that we think could produce data in 2025, ahead of product approvals, if successful. And that includes the ongoing phase II randomized trial for iNeST in CRC, that Ugur just mentioned. I think there's the potential for an interim update in the second half of 2025 or early 2026. And we've also talked about the BNT323 program in refractory and second- and third-line endometrial cancer. So those initial readouts are likely to be phase II, but we think they could have registrational potential if the data is strong. I think obviously the goal by the end of this year is to start many phase IIIs. Some of those have already started, so we could have further data updates as well from the pipeline. But those are the two that I would point you to. Thank you. Thank you. Thank you. Thank you. This concludes today's conference call. Thank you for participating. You may now disconnect.